{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28","upperLimit":"72","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"OS (overall survival) is measured from the date of study entry to the date of patient's death. If the patient is alive or his vital status is unknown, the date of death will be censored at the date that the patient is last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Romidepsin 12 mg/m2 d.1,8, 15 + Gemcitabine 800 mg/m2 d.1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 d. 1, 15 to PD\n\nRomidepsin, Gemcitabine: Romidepsin 12 mg/m2 d.1,8, 15 for 6 cycles + Gemcitabine 800 mg/m2 d.1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 d. 1, 15 to PD.","id":"OG000","title":"Romidepsin, Gemcitabine"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Overall Survival is Measured From the Date of Study Entry to the Date of Patient's Death","type":"SECONDARY","unitOfMeasure":"percentage of partecipants"}